|
DE69826695T2
(de)
*
|
1997-05-23 |
2006-02-02 |
Bayer Pharmaceuticals Corp., West Haven |
Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
|
|
EP1473292A1
(en)
*
|
1997-11-03 |
2004-11-03 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Aromatic heterocyclic compounds as anti-inflammatory agents
|
|
US7329670B1
(en)
|
1997-12-22 |
2008-02-12 |
Bayer Pharmaceuticals Corporation |
Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
|
|
US7517880B2
(en)
|
1997-12-22 |
2009-04-14 |
Bayer Pharmaceuticals Corporation |
Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
|
|
AU2006201959B2
(en)
*
|
1997-12-22 |
2008-09-04 |
Bayer Healthcare Llc |
Inhibition of Raf Kinase using Substituted Heterocyclic Ureas
|
|
DE69831013T2
(de)
*
|
1997-12-22 |
2006-04-20 |
Bayer Pharmaceuticals Corp., West Haven |
Inhibierung der raf-kinase durch substituierte heterocyclische harnstoffverbindungen
|
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
ME00275B
(me)
|
1999-01-13 |
2011-02-10 |
Bayer Corp |
ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE
|
|
US20020065296A1
(en)
*
|
1999-01-13 |
2002-05-30 |
Bayer Corporation |
Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
|
|
EP1158985B1
(en)
|
1999-01-13 |
2011-12-28 |
Bayer HealthCare LLC |
OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
|
|
CA2549558C
(en)
*
|
1999-01-13 |
2010-08-31 |
Bayer Corporation |
Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
EP1140840B1
(en)
*
|
1999-01-13 |
2006-03-22 |
Bayer Pharmaceuticals Corp. |
-g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
UA73492C2
(en)
|
1999-01-19 |
2005-08-15 |
|
Aromatic heterocyclic compounds as antiinflammatory agents
|
|
CA2360934A1
(en)
|
1999-02-22 |
2000-08-31 |
Lin-Hua Zhang |
Polycyclo heterocyclic derivatives as antiinflammatory agents
|
|
JP2002539206A
(ja)
*
|
1999-03-12 |
2002-11-19 |
ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド |
抗炎症剤としての芳香族複素環化合物
|
|
ATE278674T1
(de)
|
1999-03-12 |
2004-10-15 |
Boehringer Ingelheim Pharma |
Heterocyklischer harnstoff und verwandte verbindungen als entzündungshemmende mittel
|
|
CA2374737C
(en)
|
1999-07-09 |
2008-02-12 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Novel process for synthesis of heteroaryl-substituted urea compounds
|
|
US6387900B1
(en)
|
1999-08-12 |
2002-05-14 |
Pharmacia & Upjohn S.P.A. |
3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
|
|
WO2001012189A1
(en)
|
1999-08-12 |
2001-02-22 |
Pharmacia Italia S.P.A. |
3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents
|
|
EP1232150B1
(en)
|
1999-11-16 |
2007-10-10 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Urea derivatives as anti-inflammatory agents
|
|
SE9904177D0
(sv)
*
|
1999-11-18 |
1999-11-18 |
Astra Ab |
Novel compounds
|
|
US6525046B1
(en)
|
2000-01-18 |
2003-02-25 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Aromatic heterocyclic compounds as antiinflammatory agents
|
|
US6608052B2
(en)
|
2000-02-16 |
2003-08-19 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Compounds useful as anti-inflammatory agents
|
|
GB0010757D0
(en)
|
2000-05-05 |
2000-06-28 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0016787D0
(en)
|
2000-07-07 |
2000-08-30 |
Pfizer Ltd |
Compounds useful in therapy
|
|
FR2812633A1
(fr)
*
|
2000-08-04 |
2002-02-08 |
Aventis Cropscience Sa |
Derives de phenyl(thio)urees et phenyl(thio)carbamates fongicides
|
|
US6645990B2
(en)
|
2000-08-15 |
2003-11-11 |
Amgen Inc. |
Thiazolyl urea compounds and methods of uses
|
|
FR2815030A1
(fr)
*
|
2000-10-05 |
2002-04-12 |
Lipha |
Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant et leur utilisation pour la preparation de medicaments
|
|
AU9598601A
(en)
|
2000-10-20 |
2002-04-29 |
Eisai Co Ltd |
Nitrogenous aromatic ring compounds
|
|
JP2004517080A
(ja)
|
2000-11-29 |
2004-06-10 |
グラクソ グループ リミテッド |
Ｔｉｅ−２および／またはｖｅｇｆｒ−２の阻害剤として有用なベンゾイミダゾール誘導体
|
|
AU3405602A
(en)
*
|
2000-12-21 |
2002-07-01 |
Schering Corp |
Heteroaryl urea neuropeptide y y5 receptor antagonists
|
|
US6946476B2
(en)
|
2000-12-21 |
2005-09-20 |
Schering Corporation |
Heteroaryl urea neuropeptide Y Y5 receptor antagonists
|
|
US7235576B1
(en)
|
2001-01-12 |
2007-06-26 |
Bayer Pharmaceuticals Corporation |
Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
US7371763B2
(en)
|
2001-04-20 |
2008-05-13 |
Bayer Pharmaceuticals Corporation |
Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
|
|
DK1382604T3
(da)
*
|
2001-04-27 |
2006-04-18 |
Kirin Brewery |
Quinolinderivater med en azolylgruppe og quinazolinderivater
|
|
JP2004530690A
(ja)
|
2001-05-16 |
2004-10-07 |
ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド |
抗炎症性薬剤として有用なジアリールウレア誘導体
|
|
EP1395561A1
(en)
|
2001-05-25 |
2004-03-10 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Carbamate and oxamide compounds as inhibitors of cytokine production
|
|
EP1414810B1
(en)
|
2001-06-05 |
2006-08-30 |
Boehringer Ingelheim Pharmaceuticals Inc. |
1,4-disubstituted benzo-fused cycloalkyl urea compounds
|
|
WO2003005999A2
(en)
|
2001-07-11 |
2003-01-23 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Methods of treating cytokine mediated diseases
|
|
JP4825375B2
(ja)
*
|
2001-08-28 |
2011-11-30 |
株式会社 資生堂 |
ジチアゾール化合物及びマトリックスメタロプロテアーゼ活性阻害剤、皮膚外用剤
|
|
GB0121941D0
(en)
|
2001-09-11 |
2001-10-31 |
Astrazeneca Ab |
Chemical compounds
|
|
BR0212841A
(pt)
|
2001-09-26 |
2004-08-03 |
Pharmacia Italia Spa |
Derivado ativo de aminoindazole como inibidores de cinase, processo para sua preparação e composições farmacêuticas que os contém
|
|
EP1438048A1
(en)
|
2001-10-18 |
2004-07-21 |
Boehringer Ingelheim Pharmaceuticals Inc. |
1,4-disubstituted benzo-fused urea compounds as cytokine inhibitors
|
|
SI1478358T1
(sl)
|
2002-02-11 |
2013-09-30 |
Bayer Healthcare Llc |
Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
|
|
US20040023961A1
(en)
*
|
2002-02-11 |
2004-02-05 |
Bayer Corporation |
Aryl ureas with raf kinase and angiogenisis inhibiting activity
|
|
ATE529406T1
(de)
|
2002-02-11 |
2011-11-15 |
Bayer Healthcare Llc |
Aryl-harnstoffe als kinase inhibitoren
|
|
US10653684B2
(en)
|
2002-02-11 |
2020-05-19 |
Bayer Healthcare Llc |
Aryl ureas with angiogenisis inhibiting activity
|
|
EP1480973B1
(en)
|
2002-02-25 |
2008-02-13 |
Boehringer Ingelheim Pharmaceuticals Inc. |
1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases
|
|
MXPA04011417A
(es)
*
|
2002-05-17 |
2005-02-14 |
Pharmacia Italia Spa |
Derivados de aminoindazol activos como inhibidores de cinasa, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden.
|
|
AU2003243921B2
(en)
|
2002-06-27 |
2009-05-07 |
Novo Nordisk A/S |
Aryl carbonyl derivatives as therapeutic agents
|
|
RU2340605C2
(ru)
|
2002-06-27 |
2008-12-10 |
Ново Нордиск А/С |
Арилкарбонильные производные в качестве терапевтических средств
|
|
ES2278170T3
(es)
|
2002-07-09 |
2007-08-01 |
BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG |
Composiciones farmaceuticas de anticolinergicos e inhibidores de la quinasa p38 en el tratamiento de enfermedades respiratorias.
|
|
CN100497302C
(zh)
*
|
2002-09-05 |
2009-06-10 |
神经研究公司 |
二芳基脲衍生物和它们作为氯通道阻滞剂的用途
|
|
US7144911B2
(en)
|
2002-12-31 |
2006-12-05 |
Deciphera Pharmaceuticals Llc |
Anti-inflammatory medicaments
|
|
US7202257B2
(en)
|
2003-12-24 |
2007-04-10 |
Deciphera Pharmaceuticals, Llc |
Anti-inflammatory medicaments
|
|
ATE552236T1
(de)
*
|
2003-01-14 |
2012-04-15 |
Cytokinetics Inc |
Verbindungen, zusammensetzungen und verfahren zur behandlung von herzinsuffizienz
|
|
MXPA05009102A
(es)
*
|
2003-02-28 |
2006-05-31 |
Bayer Pharmaceuticals Corp |
Derivados de piridina sustituida utiles en el tratamiento del cancer y otros trastornos.
|
|
WO2004078748A2
(en)
|
2003-02-28 |
2004-09-16 |
Bayer Pharmaceuticals Corporation |
Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders
|
|
WO2004085433A2
(en)
*
|
2003-03-28 |
2004-10-07 |
Pharmacia & Upjohn Company Llc |
Positive allosteric modulators of the nicotinic acetylcholine receptor
|
|
EP1636585B2
(en)
|
2003-05-20 |
2012-06-13 |
Bayer HealthCare LLC |
Diaryl ureas with kinase inhibiting activity
|
|
EP1663978B1
(en)
|
2003-07-23 |
2007-11-28 |
Bayer Pharmaceuticals Corporation |
Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
|
|
US7683172B2
(en)
|
2003-11-11 |
2010-03-23 |
Eisai R&D Management Co., Ltd. |
Urea derivative and process for preparing the same
|
|
EP1684762A4
(en)
|
2003-11-13 |
2009-06-17 |
Ambit Biosciences Corp |
UREA DERIVATIVES AS MODULATORS OF KINASE
|
|
GB0330043D0
(en)
|
2003-12-24 |
2004-01-28 |
Pharmacia Italia Spa |
Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
|
|
GB0330042D0
(en)
|
2003-12-24 |
2004-01-28 |
Pharmacia Italia Spa |
Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them
|
|
BRPI0506662B8
(pt)
|
2004-01-06 |
2021-05-25 |
Novo Nordisk As |
compostos ativadores de glucoquinase
|
|
BRPI0507198A
(pt)
*
|
2004-01-30 |
2007-06-26 |
Merck Patent Gmbh |
derivados de bisariluréia
|
|
TW200530236A
(en)
|
2004-02-23 |
2005-09-16 |
Chugai Pharmaceutical Co Ltd |
Heteroaryl phenylurea
|
|
US20060211752A1
(en)
|
2004-03-16 |
2006-09-21 |
Kohn Leonard D |
Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
|
|
EP2295426A1
(en)
|
2004-04-30 |
2011-03-16 |
Bayer HealthCare, LLC |
Substituted pyrazolyl urea derivatives useful in the treatment of cancer
|
|
ES2522579T3
(es)
|
2004-06-17 |
2014-11-17 |
Cytokinetics, Inc. |
Compuestos, composiciones y métodos
|
|
EP1609789A1
(en)
*
|
2004-06-23 |
2005-12-28 |
Eli Lilly And Company |
Ureido-pyrazole derivatives and their use as kinase inhibitors
|
|
US20060035893A1
(en)
|
2004-08-07 |
2006-02-16 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
|
|
ATE428421T1
(de)
|
2004-09-17 |
2009-05-15 |
Eisai R&D Man Co Ltd |
Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften
|
|
US7612200B2
(en)
|
2004-12-07 |
2009-11-03 |
Locus Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
|
US7741479B2
(en)
|
2004-12-07 |
2010-06-22 |
Locus Pharmaceuticals, Inc. |
Urea inhibitors of MAP kinases
|
|
PE20060777A1
(es)
|
2004-12-24 |
2006-10-06 |
Boehringer Ingelheim Int |
Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
|
|
ATE482693T1
(de)
|
2005-03-07 |
2010-10-15 |
Bayer Schering Pharma Ag |
Pharmazeutische zusammensetzung mit einem omega- carboxyaryl-substituierten diphenylharnstoff zur behandlung von krebs
|
|
DE102005015253A1
(de)
|
2005-04-04 |
2006-10-05 |
Merck Patent Gmbh |
Pyrazolderivate
|
|
JP4989476B2
(ja)
|
2005-08-02 |
2012-08-01 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
血管新生阻害物質の効果を検定する方法
|
|
US7538223B2
(en)
|
2005-08-04 |
2009-05-26 |
Cytokinetics, Inc. |
Compounds, compositions and methods
|
|
DE102005037499A1
(de)
|
2005-08-09 |
2007-02-15 |
Merck Patent Gmbh |
Pyrazolderivate
|
|
US8217042B2
(en)
|
2005-11-11 |
2012-07-10 |
Zentaris Gmbh |
Pyridopyrazines and their use as modulators of kinases
|
|
EP1790342A1
(de)
|
2005-11-11 |
2007-05-30 |
Zentaris GmbH |
Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege
|
|
WO2007054556A1
(de)
|
2005-11-11 |
2007-05-18 |
Æterna Zentaris Gmbh |
Neue pyridopyrazine und deren verwendung als modulatoren von kinasen
|
|
ES2419007T3
(es)
|
2005-12-15 |
2013-08-19 |
Cytokinetics, Inc. |
Ciertas entidades químicas, composiciones y procedimientos
|
|
US7825120B2
(en)
|
2005-12-15 |
2010-11-02 |
Cytokinetics, Inc. |
Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
|
|
WO2007078815A2
(en)
|
2005-12-16 |
2007-07-12 |
Cytokinetics, Inc. |
Certain chemical entities, compositions, and methods
|
|
WO2007078839A2
(en)
|
2005-12-19 |
2007-07-12 |
Cytokinetics, Inc. |
Compounds, compositions and methods
|
|
WO2007075650A2
(en)
*
|
2005-12-21 |
2007-07-05 |
Bayer Healthcare Ag |
Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders
|
|
WO2007076460A2
(en)
*
|
2005-12-23 |
2007-07-05 |
Kalypsys, Inc. |
Substituted thiazole ureas useful as inhibitors of protein kinases
|
|
CN104706637A
(zh)
|
2006-05-18 |
2015-06-17 |
卫材R&D管理有限公司 |
针对甲状腺癌的抗肿瘤剂
|
|
EP2094268A2
(en)
|
2006-05-26 |
2009-09-02 |
Bayer HealthCare, LLC |
Drug combinations with substituted diaryl ureas for the treatment of cancer
|
|
DE102006029795A1
(de)
*
|
2006-06-27 |
2008-01-03 |
Schebo Biotech Ag |
Neue Harnstoff-Derivate und deren Verwendungen
|
|
WO2008026748A1
(en)
|
2006-08-28 |
2008-03-06 |
Eisai R & D Management Co., Ltd. |
Antitumor agent for undifferentiated gastric cancer
|
|
US7897762B2
(en)
|
2006-09-14 |
2011-03-01 |
Deciphera Pharmaceuticals, Llc |
Kinase inhibitors useful for the treatment of proliferative diseases
|
|
JP2010514692A
(ja)
|
2006-12-20 |
2010-05-06 |
バイエル ヘルスケア リミティド ライアビリティ カンパニー |
癌の治療に有用なヒドロキシメチルフェニルピラゾリル尿素化合物
|
|
CA2676796C
(en)
|
2007-01-29 |
2016-02-23 |
Eisai R & D Management Co., Ltd. |
Composition for treatment of undifferentiated gastric cancer
|
|
WO2008125014A1
(fr)
*
|
2007-04-13 |
2008-10-23 |
Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. |
Composés d'urée, leurs procédés de préparation et leurs utilisations pharmaceutiques
|
|
WO2008131276A1
(en)
|
2007-04-20 |
2008-10-30 |
Deciphera Pharmaceuticals, Llc |
Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
|
|
EP1992344A1
(en)
|
2007-05-18 |
2008-11-19 |
Institut Curie |
P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
|
|
US8952035B2
(en)
|
2007-11-09 |
2015-02-10 |
Eisai R&D Management Co., Ltd. |
Combination of anti-angiogenic substance and anti-tumor platinum complex
|
|
JP2012504591A
(ja)
|
2008-10-02 |
2012-02-23 |
レスピバート・リミテツド |
ｐ３８ＭＡＰキナーゼ阻害剤
|
|
GB0818033D0
(en)
|
2008-10-02 |
2008-11-05 |
Respivert Ltd |
Novel compound
|
|
MX2011006219A
(es)
*
|
2008-12-11 |
2011-06-28 |
Respivert Ltd |
Inhibidores de la proteina cinasa activada por el mitogeno p38.
|
|
GB0905955D0
(en)
|
2009-04-06 |
2009-05-20 |
Respivert Ltd |
Novel compounds
|
|
MX2012001974A
(es)
*
|
2009-08-19 |
2012-04-11 |
Ambit Biosciences Corp |
Compuestos de biarilo y metodos de uso de los mismos.
|
|
MY162940A
(en)
|
2009-08-19 |
2017-07-31 |
Eisai R&D Man Co Ltd |
Quinoline derivative-containing pharmaceutical composition
|
|
CN102958523B
(zh)
|
2010-06-25 |
2014-11-19 |
卫材R&D管理有限公司 |
使用具有激酶抑制作用的组合的抗肿瘤剂
|
|
CA2805874A1
(en)
|
2010-07-19 |
2012-01-26 |
Bayer Healthcare Llc |
Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
|
|
EP2508184A1
(en)
|
2011-04-06 |
2012-10-10 |
Æterna Zentaris GmbH |
Pyridopyrazine derivatives and their use
|
|
CN103402519B
(zh)
|
2011-04-18 |
2015-11-25 |
卫材R&D管理有限公司 |
肿瘤治疗剂
|
|
JP6038128B2
(ja)
|
2011-06-03 |
2016-12-07 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
|
|
CN103172648B
(zh)
*
|
2011-12-20 |
2016-05-25 |
上海迪诺医药科技有限公司 |
三杂环衍生物、制备方法及应用
|
|
ES2897740T3
(es)
|
2011-12-28 |
2022-03-02 |
Kyoto Prefectural Public Univ Corp |
Normalización del cultivo de células endoteliales de la córnea
|
|
US8461179B1
(en)
|
2012-06-07 |
2013-06-11 |
Deciphera Pharmaceuticals, Llc |
Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
|
|
US20150225373A1
(en)
*
|
2012-08-29 |
2015-08-13 |
Respivert Limited |
Kinase inhibitors
|
|
MX374242B
(es)
|
2012-11-13 |
2025-03-05 |
Array Biopharma Inc |
Compuestos de n-pirrolidinil, n' -pirazolil-urea, tiourea, guanidina y cianoguanidina como inhibidores de trka cinasa.
|
|
RS55593B1
(sr)
|
2012-11-13 |
2017-06-30 |
Array Biopharma Inc |
Jedinjenja biciklične uree, tiouree, guanidina i cijanoguanidina korisna za lečenje bola
|
|
KR20150098605A
(ko)
|
2012-12-21 |
2015-08-28 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
퀴놀린 유도체의 비정질 형태 및 그의 제조방법
|
|
AU2014219855B2
(en)
*
|
2013-02-19 |
2017-09-28 |
Ono Pharmaceutical Co., Ltd. |
Trk-inhibiting compound
|
|
NZ714049A
(en)
|
2013-05-14 |
2020-05-29 |
Eisai R&D Man Co Ltd |
Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
|
|
WO2015066490A1
(en)
|
2013-10-31 |
2015-05-07 |
Ohio University |
Prevention and treatment of non-alcoholic fatty liver disease
|
|
WO2015072580A1
(ja)
|
2013-11-14 |
2015-05-21 |
学校法人同志社 |
細胞増殖促進または細胞障害抑制による角膜内皮治療薬
|
|
MA40434B1
(fr)
|
2014-05-15 |
2019-09-30 |
Array Biopharma Inc |
1-((3s,4r)-4-(3-fluorophényl)-1-(2-méthoxyéthyl)pyrrolidin-3-yl)-3-(4-méthyl-3-(2-méthylpyrimidin-5-yl)-1-phényl-1h-pyrazol-5-yl)urée comme inhibiteur de la kinase trka
|
|
US10392381B2
(en)
|
2014-07-18 |
2019-08-27 |
Ohio University |
Prevention and treatment of non-alcoholic fatty liver disease
|
|
EP3180335B1
(en)
|
2014-08-11 |
2021-05-05 |
Angion Biomedica Corporation |
Cytochrome p450 inhibitors and uses thereof
|
|
PT3524595T
(pt)
|
2014-08-28 |
2022-09-19 |
Eisai R&D Man Co Ltd |
Derivado de quinolina altamente puro e método para produção do mesmo
|
|
WO2016037578A1
(en)
|
2014-09-10 |
2016-03-17 |
Glaxosmithkline Intellectual Property Development Limited |
Novel compounds as rearranged during transfection (ret) inhibitors
|
|
WO2016038552A1
(en)
|
2014-09-10 |
2016-03-17 |
Glaxosmithkline Intellectual Property Development Limited |
Pyridone derivatives as rearranged during transfection (ret) kinase inhibitors
|
|
US9638690B2
(en)
|
2014-11-07 |
2017-05-02 |
The University Of British Columbia |
Compounds and compositions for use as alkylating agent sensors and methods of use thereof
|
|
CA2970819A1
(en)
|
2014-12-31 |
2016-07-07 |
Angion Biomedica Corp. |
Methods and agents for treating disease
|
|
LT3263106T
(lt)
|
2015-02-25 |
2024-01-10 |
Eisai R&D Management Co., Ltd. |
Chinolino darinių kartumo sumažinimo būdas
|
|
KR102662228B1
(ko)
|
2015-03-04 |
2024-05-02 |
머크 샤프 앤드 돔 코포레이션 |
암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
|
|
MX373231B
(es)
|
2015-06-16 |
2020-05-08 |
Eisai R&D Man Co Ltd |
Agente anticancerigeno.
|
|
US12220398B2
(en)
|
2015-08-20 |
2025-02-11 |
Eisai R&D Management Co., Ltd. |
Tumor therapeutic agent
|
|
US12303505B2
(en)
|
2017-02-08 |
2025-05-20 |
Eisai R&D Management Co., Ltd. |
Tumor-treating pharmaceutical composition
|
|
RU2019134940A
(ru)
|
2017-05-16 |
2021-06-16 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Лечение гепатоцеллюлярной карциномы
|
|
IL276398B2
(en)
|
2018-01-31 |
2026-03-01 |
Deciphera Pharmaceuticals Llc |
Combination therapy for mastocytosis
|
|
CN118416236A
(zh)
|
2018-01-31 |
2024-08-02 |
德西费拉制药有限责任公司 |
治疗胃肠道间质瘤的组合疗法
|
|
CN112040945A
(zh)
|
2018-06-12 |
2020-12-04 |
Vtv治疗有限责任公司 |
葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途
|
|
WO2020185812A1
(en)
|
2019-03-11 |
2020-09-17 |
Teva Pharmaceuticals International Gmbh |
Solid state forms of ripretinib
|
|
EP4013412B1
(en)
|
2019-08-12 |
2026-01-28 |
Deciphera Pharmaceuticals, LLC |
Ripretinib for treating gastrointestinal stromal tumors
|
|
TWI878335B
(zh)
|
2019-08-12 |
2025-04-01 |
美商迪賽孚爾製藥有限公司 |
治療胃腸道基質瘤方法
|
|
EP4084779B1
(en)
|
2019-12-30 |
2024-10-09 |
Deciphera Pharmaceuticals, LLC |
Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
|
|
MX2022008103A
(es)
|
2019-12-30 |
2022-09-19 |
Deciphera Pharmaceuticals Llc |
Formulaciones de inhibidores de la cinasa amorfa y metodos de estas.
|
|
US12391658B2
(en)
|
2020-02-18 |
2025-08-19 |
Vtv Therapeutics Llc |
Sulfoxide and sulfone glucokinase activators and methods of use thereof
|
|
CN116102522A
(zh)
*
|
2021-11-09 |
2023-05-12 |
河南省化工研究所有限责任公司 |
一种阳离子蓝染料中间体的制备方法
|
|
US11779572B1
(en)
|
2022-09-02 |
2023-10-10 |
Deciphera Pharmaceuticals, Llc |
Methods of treating gastrointestinal stromal tumors
|